Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Complications of biologic therapy for pediatric cancer - What the surgeon needs to know.

Seminars in pediatric surgery

Malek MM.
PMID: 31931961
Semin Pediatr Surg. 2019 Dec;28(6):150863. doi: 10.1016/j.sempedsurg.2019.150863. Epub 2019 Nov 20.

Biologic therapy for pediatric cancer has gained much enthusiasm over the past two decades. Recent advances in the clinical sequencing of tumors, have also allowed for the identification of targetable mutations. These findings have created a new avenue of...

Cite
Malek MM. Complications of biologic therapy for pediatric cancer - What the surgeon needs to know. Semin Pediatr Surg. 2019;28(6):150863doi: 10.1016/j.sempedsurg.2019.150863.
Malek, M. M. (2019). Complications of biologic therapy for pediatric cancer - What the surgeon needs to know. Seminars in pediatric surgery, 28(6), 150863. https://doi.org/10.1016/j.sempedsurg.2019.150863
Malek, Marcus M. "Complications of biologic therapy for pediatric cancer - What the surgeon needs to know." Seminars in pediatric surgery vol. 28,6 (2019): 150863. doi: https://doi.org/10.1016/j.sempedsurg.2019.150863
Malek MM. Complications of biologic therapy for pediatric cancer - What the surgeon needs to know. Semin Pediatr Surg. 2019 Dec;28(6):150863. doi: 10.1016/j.sempedsurg.2019.150863. Epub 2019 Nov 20. PMID: 31931961.
Copy Download .nbib Format: NLM
Biosimilars: A new scenario in biologic therapies.

Reumatologia clinica

Serra López-Matencio JM, Morell Baladrón A, Castañeda S.
PMID: 27372258
Reumatol Clin. 2017 Sep - Oct;13(5):287-293. doi: 10.1016/j.reuma.2016.05.013. Epub 2016 Jun 29.

There is no doubt that biologic therapies provide added value for health systems. However, due to their special nature, they also raise some questions that make highly rigorous and demanding quality control and monitoring of their use indispensable. This...

Cite
Serra López-Matencio JM, Morell Baladrón A, Castañeda S. Fármacos biosimilares: un nuevo escenario en las terapias biológicas. Biosimilars: A new scenario in biologic therapies. Reumatol Clin. 2016;13(5):287-293doi: 10.1016/j.reuma.2016.05.013.
Serra López-Matencio, J. M., Morell Baladrón, A., & Castañeda, S. (2017). Fármacos biosimilares: un nuevo escenario en las terapias biológicas. Biosimilars: A new scenario in biologic therapies. Reumatologia clinica, 13(5), 287-293. https://doi.org/10.1016/j.reuma.2016.05.013
Serra López-Matencio, José M, et al. "Fármacos biosimilares: un nuevo escenario en las terapias biológicas." Biosimilars: A new scenario in biologic therapies. Reumatologia clinica vol. 13,5 (2017): 287-293. doi: https://doi.org/10.1016/j.reuma.2016.05.013
Serra López-Matencio JM, Morell Baladrón A, Castañeda S. Fármacos biosimilares: un nuevo escenario en las terapias biológicas. Biosimilars: A new scenario in biologic therapies. Reumatol Clin. 2017 Sep - Oct;13(5):287-293. doi: 10.1016/j.reuma.2016.05.013. Epub 2016 Jun 29. Spanish. PMID: 27372258.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries